Continuous renal replacement therapy (CRRT) in intensive care unit (ICU) patients with acute renal of the extracorporeal circuit blood. This is usually 1 2 or hirudin 3 seen in approximately 10 to 30% of haemodialysis treatments and 30 to 50% in CRRT 11 .
total daily clearance 12 .
CRRT have been proposed delivery due to combined infusion of trisodium (CVVHf) in predilution mode (i.e. infusion at the 21 . This approach 140 mmol/l. Furthermore citrate is the only buffer buffered substitution fluid Clinic for Nephrology, University Hospital, Düsseldorf, Germany Different methods of regional anticoagulation using citrate in continuous renal replacement therapy have been described in the past. However, these procedures were usually very complex or did not reach modern requirements for effective continuous renal replacement therapy. Furthermore, little is known about long-term acid-base stability and citrate levels during the treatment. We describe a system in which citrate is used both as anticoagulant and as the sole buffer substance in continuous venovenous haemofiltration. Our citrate-containing, calcium-free substitution fluid was used in predilution mode with a constant ratio between blood flow (120 to 150 ml/min) and substitution flow (2400 to 3000 ml/hour). Anticoagulation was limited to the extracorporeal circuit. Twenty patients with acute renal failure on mechanical ventilation were treated, four for eight hours, four for 24 hours and 12 as long they needed continuous renal replacement therapy (9.6±5.0 days, range 4.0 to 39.3 days). We achieved stable acid-base and electrolyte balance in all patients. We observed no bleeding complications (patient activated clotting time 112.4±17.1 s, post-filter circuit activated clotting time 270.5±80.3 s) and achieved appropriate filter life times (48.6±13.2 h).
Predilution, citrate-based substitution fluid provides both anticoagulation within the extracorporeal circuit and control of acid-base balance in critically ill patients at risk of bleeding in acute renal failure. It is easy to apply and safe. Clearance can be varied as long as a constant ratio between blood and substitution flow is maintained.
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an inconstant ratio of citrate to calcium infusion. 22 . The described procedure is only suitable for CVVHf and cannot be adapted for use with continuous venovenous haemodialysis. It may be adapted for use with continuous reported in a similar system 15 20 patients treated with CVVHf and citrate as the
Study design and population
The study was approved by the local ethical committee. We studied 20 patients on our internal medicine intensive care unit with ARF. All patients were on mechanical ventilation and had an arterial line in situ. All patients were treated times were monitored. All values are presented metabolic stability. The next four patients were . So far only one randomised crossover trial 24 with 20 patients has addressed the hypernatraemia. This is due to the composition of calcium should be below 0.3 mmol/l 22 value was achieved with the procedure described here venovenous hemofiltration: a prospective randomized study.
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